TeamDrive
RUS
Vladimir Gurdus

Vladimir Gurdus

Founding Partner, COO

Телефоны:

+7 495 545-39-12

Send message

Vladimir is the co-founder and member of the Board of Directors of Doctor Ryadom (a private network of medical clinics). He is also the CEO and founder partner of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is Russian innovation pharmaceutical company NovaMedica LLC.

Vladimir is one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the U.S. firm Domain Associates LLC. RusnanoMedInvest was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Before assuming a key role as one of the project’s leaders and founding Team Drive, from 2007 to 2009 Vladimir was President at Medsi Group (part of AFK Sistema) and played a key role in transforming it into the leading privately-held medical service provider. Previously he had played an active role in starting up the ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding.  From 1991 to 2007 he was First Deputy CEO of ROSNO, and also the COO and CEO of ROSNO Group subsidiaries, such as ROSNO-MS. In 2006, after the acquisition of ROSNO by Allianz, Vladimir was appointed CEO of Allianz ROSNO-Life.

He is also an investor and the founder of a number of successful start-ups in the medical, insurance and IT sectors.

Vladimir is a member of the Government Expert Council of the Russian Federation. This organisation was established to involve the business community in the preparation and implementation of the decisions of the Russian Government, and also to ensure public oversight over the work of the federal authorities. Members of the Council attend the meetings of the Russian government, government and interdepartmental commissions and committees, and perform expert reviews of the draft decisions of the Russian government and federal executive agencies and the results of implementation. As a member of the Expert Council Vladimir proactively tackles issues of developing the Russian healthcare and pharmaceutical sectors. He also co-chairs a joint working group of the Expert Council and the Ministry of Health, whose chief remit is to draft the development framework of a healthcare system and the provision of the medicines required by the Russian population drug.

Vladimir is a member of the Public Council under the Ministry of Health of the Russian Federation – a permanent consultative public health oversight body.

Vladimir graduated cum laude from I.M. Sechenov Moscow Medical Academy. He has a second degree in finance and economics at RosNOU. Vladimir is a Doctor of Medical Sciences and Professor.

Media Center

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

  • 18 October 2018

    Russia emerges as frontrunner in global fight against tuberculosis

    Russia has turned out to be the world’s most successful tuberculosis fighter, Russian Health Minister Veronika Skvortsova stated  during the interview with the Rossiya-24 channel. "We are the global leader according to the pace in solving this issue," she noted, adding, "all countries acknowledge Russia’s foremost role here."

  • 17 October 2018

    Scientists developed new tool for open exchange of biomaterials

    A new easy-to-use legal tool that enables open exchange of biological materials was launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within which research organisations define terms and conditions for sharing their materials – everything from DNA molecules to plant seeds to patient samples.

  • 16 October 2018

    The First FDA-approved Digital Pill — What It Means for Pharma

    Last year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. From there the information is wirelessly sent to a mobile phone app, allowing both the patient and her physician to track how the patient is using and responding to her medication.

Read more